Triple negative breast cancer is an aggressive type of breast cancer in which the tumor cells lack receptors for estrogen, progesterone and the HER2 protein on their surfaces. Because the tumor cells lack these receptors, treatments such as hormone therapy, like tamoxifen and aromatase inhibitors, or drugs that target HER2, like Herceptin, are not effective.
In this video, Dr. Sara Chumsri, a member of the UMGCC Breast Evaluation and Treatment Program, discusses triple negative breast cancer and some of the promising new research underway to develop new therapies to successfully treat this type of breast cancer.